NYMOX PHARMACEUTICAL REPORTS NX-1207 STUDY DATA

A A

Nymox Pharmaceutical has reported that a review of safety data for its ongoing multi-center Phase II trial of its lead drug candidate NX-1207, for treatment of benign prostatic hyperplasia, has revealed no serious drug side effects.

Nymox said NX-1207 had completed two earlier Phase I and II trials where the drug produced on average over 23 percent prostate shrinkage in 1 month with minimal side effects. The symptomatic improvement in earlier trials reached 10 points on the benign prostatic hyperplasia symptom score, which, the company said, was far superior to available drugs, and compares to invasive and surgical treatments.